-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Neurocrine Biosciences and Sosei Heptares announced a strategic cooperation and licensing agreement to jointly develop new selective muscarinic receptor agonists for the treatment of schizophrenia, dementia and other neurological diseases
Muscarinic receptors are essential for brain function and have been verified as drug targets for psychosis and cognitive impairment
Based on this platform, the company has discovered a variety of selective muscarinic M4, M1 and M1/M4 dual agonists, which have potential therapeutic effects while avoiding the harmful side effects caused by non-selective agonists
According to the agreement, Neurocrine Biosciences will obtain the right to develop and commercialize the new selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares
In addition to the M1 agonist being developed in Japan, Neurocrine Biosciences will be responsible for development costs related to global R&D projects
Reference materials:
[1] Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders.
(The original text has been deleted)